NovaBay Pharmaceuticals (NBY) Profit After Tax (2016 - 2025)
Historic Profit After Tax for NovaBay Pharmaceuticals (NBY) over the last 17 years, with Q3 2025 value amounting to -$1.3 million.
- NovaBay Pharmaceuticals' Profit After Tax rose 2810.14% to -$1.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$5.1 million, marking a year-over-year increase of 5220.7%. This contributed to the annual value of -$7.2 million for FY2024, which is 2507.26% up from last year.
- NovaBay Pharmaceuticals' Profit After Tax amounted to -$1.3 million in Q3 2025, which was up 2810.14% from -$371000.0 recorded in Q4 2024.
- NovaBay Pharmaceuticals' Profit After Tax's 5-year high stood at -$111000.0 during Q1 2022, with a 5-year trough of -$8.2 million in Q4 2022.
- In the last 5 years, NovaBay Pharmaceuticals' Profit After Tax had a median value of -$1.8 million in 2023 and averaged -$2.0 million.
- The largest annual percentage gain for NovaBay Pharmaceuticals' Profit After Tax in the last 5 years was 9405.85% (2022), contrasted with its biggest fall of 509367.09% (2022).
- Quarter analysis of 5 years shows NovaBay Pharmaceuticals' Profit After Tax stood at -$158000.0 in 2021, then crashed by 5093.67% to -$8.2 million in 2022, then soared by 49.94% to -$4.1 million in 2023, then skyrocketed by 90.97% to -$371000.0 in 2024, then crashed by 259.3% to -$1.3 million in 2025.
- Its Profit After Tax stands at -$1.3 million for Q3 2025, versus -$371000.0 for Q4 2024 and -$1.9 million for Q3 2024.